LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Disrupted Micronuclei Cited as Potential Non-Small-Cell Lung Cancer Biomarkers

By LabMedica International staff writers
Posted on 16 Jul 2013
Cancer researchers have found that collapse of the nuclear membrane that surrounds micronuclei—bits of the genome that become detached during cell replication—may allow these damaged segments of DNA to reenter the cell's genetic material with possible cancer-causing consequences.

Investigators at the Salk Institute for Biological Sciences (La Jolla, CA, USA) worked with cultures of non-small-cell lung cancer (NSCLC) cells. They reported in the July 3, 2013, issue of the journal Cell that micronuclei, which were sometimes generated when these cells replicated, had reduced functioning compared to primary nuclei in the same cell, although the two compartments appeared to be structurally comparable. Over 60% of micronuclei were found to undergo an irreversible loss of compartmentalization during interphase due to collapse of their nuclear envelope.

The disruption of the micronuclei, which was induced by defects in nuclear lamina assembly, drastically reduced nuclear functions and had the potential to trigger massive DNA damage. Disruption of micronuclei was associated with chromatin compaction and invasion of endoplasmic reticulum (ER) tubules into the chromatin.

Disrupted micronuclei were detected in both major subtypes of NSCLC, suggesting that this feature could be a useful objective biomarker for genomic instability in solid tumors.

"Our study shows that more than 60% of micronuclei undergo catastrophic dysfunction in solid tumors such as NSCLC," said senior author Dr. Martin Hetzer, professor of molecular and cell biology at the Salk Institute for Biological Sciences. "We identified disrupted micronuclei in two major subtypes of human non-small-cell lung cancer, which suggests that they could be a valuable tool for cancer diagnosis."

Related Links:
Salk Institute for Biological Sciences


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more